Journal
JOURNAL OF NANOBIOTECHNOLOGY
Volume 20, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s12951-022-01429-2
Keywords
Cancer immunotherapy; Nanovesicles; Liposomes; Cell membrane vesicles; Bacterial outer membrane vesicles; Extracellular vesicles; Hybrid nanovesicles
Funding
- high-level talents (333 Project) of Jiangsu Province [BRA2019024]
- Key Project Foundation of Jiangsu Health and Health Committee [H2018114]
- Social Development Project of the Key Research and Development Plan of Jiangsu Province [BE2018606]
- China Postdoctoral Science Foundation [2018M630605]
Ask authors/readers for more resources
Immunotherapy has emerged as a promising anticancer therapy, with the ability to activate immune cells, regulate the tumor immune microenvironment, and deliver drugs. Lipid nanovesicles as a drug delivery system have important applications in cancer immunotherapy.
Immunotherapy has gradually emerged as the most promising anticancer therapy. In addition to conventional anti-PD-1/PD-L1 therapy, anti-CTLA-4 therapy, CAR-T therapy, etc., immunotherapy can also be induced by stimulating the maturation of immune cells or inhibiting negative immune cells, regulating the tumor immune microenvironment and cancer vaccines. Lipid nanovesicle drug delivery system includes liposomes, cell membrane vesicles, bacterial outer membrane vesicles, extracellular vesicles and hybrid vesicles. Lipid nanovesicles can be used as functional vesicles for cancer immunotherapy, and can also be used as drug carriers to deliver immunotherapy drugs to the tumor site for cancer immunotherapy. Here, we review recent advances in five kinds of lipid nanovesicles in cancer immunotherapy and assess the clinical application prospects of various lipid nanovesicles, hoping to provide valuable information for clinical translation in the future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available